Potentially Disruptive Medtech Company Wins FDA Nod for HF Therapy
One of the 16 promising medtech companies in the private sector, as named in a Canaccord Genuity analyst report, earlier this year, has just received approval for its heart failure therapy. Impulse Dynamics noted it nabbed a nod from FDA for the Optimizer Smart System.
The Orangeburg, NY-based companyâs technology delivers Cardiac Contractility Modulation (CCM). Through CGM an electrical pulse is delivered during the absolute refractory period, which is just after heart contracts. In contrast to a pacemaker or defibrillator, CCM works by modulating the strength of the heart muscle contraction rather than the rhythm.
Daniel Burkhoff, MD, PhD, of Impulse Dynamics described how the Optimizer Smart System worked and noted how it could be beneficial to patients.
âThis therapy has been focuses on helping the muscle [in the heart] get better, if you will,â Burkhoff, told MD+DI. âIn the failing space the muscle in the heart undergoes a lot of changes in the molecular level and the genetic level. We have found that these electrical signals that we apply can have beneficial effects to help restore a more normal molecular makeup. In that regard that is what we believe is contributing to helping these patients feel better.â
Burkhoff noted that in a âbroad senseâ the technology shared some similarities to electroceuticals - bioelectronic devices implanted in the bo...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
More News: Biology | Cardiology | Cardiovascular | Contracts | Cytology | Genetics | Heart | Heart Failure | Learning | Medical Devices | Molecular Biology | Physiology | Universities & Medical Training